Related Tags >> Licensing deals Development deals Merck KgAA Apitope Technology

Merck Serono News

Most Popular Merck Serono Story

Merck Serono, Theratechnologies ink $215M deal

October 29, 2008 — 10:00am ET | By Maureen Martino

Merck Serono has signed a deal to license the U.S. commercialization right to tesamorelin, a drug to treat excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains rights to... Read more...

Merck Serono Press Releases

NICE Recommends Use Of Cetuximab (Erbitux(R)) For UK Bowel Cancer Patients
Results at ASCO Congress 2009 Highlight Merck Serono's Leadership in Personalizing Cancer Care
Merck Serono Launches Glucophage(R) Powder (Metformin Hydrochloride) in First European Countries
Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate

Latest Headlines

NovImmune raises $54.8M to buy back drug rights
May 12, 2009
Merck Serono to invest $55M in start-up biotechs
March 23, 2009
Apitope wins 154M euro deal for MS therapy
January 13, 2009
Merck Serono, Theratechnologies ink $215M deal
October 29, 2008
Ablynx gains partner in $340M nanobody deal
September 4, 2008
Merck Serono, Bionomics partner on MS programs
June 18, 2008
ALSO NOTED: Pfizer to buy CovX; Florida commits $94M to Max Planck; Affymetrix buys USB; HGS touts animal trial results for ant
December 18, 2007
ALSO NOTED: Ventana and Roche forge confidentiality agreement; Rigel wins $3M payment; and much more...
November 14, 2007
DEALS: Solvay, Merck Serono ink deals with Gene Logic
August 30, 2007
Matuzumab in doubt after trial failure
August 29, 2007
Gene Logic takes fresh look at Merck KGaA drugs
August 24, 2007

Paid Research Reports

More Research Reports >>